Therapeutic Asset Ratings

13,150 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Binimetinib Colorectal Carcinoma	Roswell Park Cancer Institute	P2	CCC (55)
Binimetinib Refractory Malignant Neoplasm	N.N. Petrov National Medical Research Center of Oncology	P2	CCC (55)
Brentuximab Vedotin Primary Cutaneous Lymphoma	M.D. Anderson Cancer Center	P2	CCC (55)
Brentuximab Vedotin Lymphatic System Disorder	UNC Lineberger Comprehensive Cancer Center	P2	CCC (55)
Brentuximab Vedotin Lymphomatoid Papulosis	Memorial Sloan Kettering Cancer Center	P2	CCC (55)
Brexucabtagene Autoleucel Mantle Cell Lymphoma	Vanderbilt-Ingram Cancer Center	P2	CCC (55)
Burosumab Fibrous Dysplasia	National Institute of Dental and Craniofacial Research (NIDCR)	P2	CCC (55)
Busulfanum Aspartylglucosaminuria	Masonic Cancer Center, University of Minnesota	P2	CCC (55)
Busulfanum Therapy-Related Myeloid Neoplasm	M.D. Anderson Cancer Center	P2	CCC (55)
Busulfanum Inborn Error Of Immunity	medac GmbH	P2	CCC (55)
Busulfanum Mucopolysaccharidosis Type 2	Masonic Cancer Center, University of Minnesota	P2	CCC (55)
Busulfanum Hurler Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (55)
Busulfanum Langerhans Cell Histiocytosis	M.D. Anderson Cancer Center	P2	CCC (55)
Busulfanum Mucopolysaccharidosis	Masonic Cancer Center, University of Minnesota	P2	CCC (55)
Busulfanum Peroxisomal Disease	Masonic Cancer Center, University of Minnesota	P2	CCC (55)
Busulfanum Mucopolysaccharidosis Type 7	Masonic Cancer Center, University of Minnesota	P2	CCC (55)
Busulfanum Sphingolipidosis	Masonic Cancer Center, University of Minnesota	P2	CCC (55)
Cabergoline Polycystic Ovary Syndrome	Al-Rasheed University College	P2	CCC (55)
Cabozantinib Metastatic Malignant Neoplasm In The Brain	Memorial Sloan Kettering Cancer Center	P2	CCC (55)
Cabozantinib Chromophobe Renal Cell Carcinoma	Bradley A. McGregor, MD	P2	CCC (55)
Cabozantinib Collecting Duct Carcinoma	Bradley A. McGregor, MD	P2	CCC (55)
Cabozantinib Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	P2	CCC (55)
Cabozantinib Neoplasm	Arcus Biosciences, Inc.	P2	CCC (55)
Cabozantinib Urethra Neoplasm	National Cancer Institute (NCI)	P2	CCC (55)
Capecitabine Gastrin-Producing Neuroendocrine Tumor	ECOG-ACRIN Cancer Research Group	P2	CCC (55)

Showing 2651 to 2675 of 13,150 assets

PreviousPage 107 of 526Next